PUBLICATIONS H-Index: 65 To assess the publications online, please go to

Publications
-1-
Prof. Daniel Speiser
PUBLICATIONS
Current H-Index: 65
To assess the publications online, please go to http://www.ncbi.nlm.nih.gov/pubmed?term=speiser%20d,
or to http://serval.unil.ch/search (and search for “speiser” or “daniel speiser”).
Publications 2012 – mid 2017:
1.
Baitsch L., A. Legat, L. Barba, S.A. Fuertes Marraco, J.P. Rivals, P. Baumgaertner, C. Christiansen-Jucht,
H. Bouzourene, D. Rimoldi, H. Pircher, N. Rufer, M. Matter, O. Michielin and D.E. Speiser. Extended co-expression
of inhibitory receptors by human CD8 T cells depending on differentiation, antigen-specificity and anatomical
localization. PLoS One 2012. 7(2):e30852.
2.
Baumgaertner P., C. Jandus, J.P. Rivals, L. Derré, T. Lövgren, L. Baitsch, P. Guillaume, I.F. Luescher, G.
Berthod, M. Matter, N. Rufer, O. Michielin and D.E. Speiser. Vaccination-induced functional competence of
circulating human cancer-specific CD8 T cells. International Journal of Cancer 2012. 130: 2601-2617.
3.
Braun M., C. Jandus, P. Maurer, A. Hammann-Haenni, K. Schwarz, M.F. Bachmann, D.E. Speiser and P.
Romero. Virus-like particles induce robust human T helper cell responses. European Journal of Immunology
2012. 42:330-340.
4.
Lövgren T., P. Baumgaertner, S. Wieckowski, E. Devêvre, P. Guillaume, I. Luescher, N. Rufer and D.E.
Speiser. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination
with low peptide dose. Cancer Immunology Immunotherapy 2012. 61:817-826.
5.
Romero P. and D.E. Speiser. Melanoma vaccines. Book Chapter in “Targeted Therapeutics in
Melanoma”, T.F. Gajewski and F.S. Hodi (Eds), Humana Press 2012, XIV: 207-232.
6.
Baitsch L., S.A. Fuertes Marraco, A. Legat, Ch. Meyer and D.E. Speiser. The three main stumbling blocks
for anti-cancer T cells. Review Article. Trends in Immunology 2012. 33: 364-372.
7.
Speiser D.E. A molecular profile of T cell exhaustion in cancer. Review Article. Onco-Immunology May
2012. 1: 369-371.
8.
Berthod G., R. Lazor, I. Letovanec, E. Romano, L. Noirez, J. Mazza-Stalder, D.E. Speiser, S. Peters and
O. Michielin. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. Journal of Clinical Oncology 2012.
30:e156-159.
9.
Irving M.B., V. Zoete, M. Hebeisen, D. Schmid, P. Baumgaertner, P. Guillaume, P. Romero, D.E. Speiser,
I. Luescher, N. Rufer and O. Michielin. Interplay between T cell receptor binding kinetics and the level of cognate
peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. Journal of
Biological Chemistry 2012. 287:23068-23078.
10.
Mahnke Y., E. Devêvre, P. Baumgaertner, M. Matter, N. Rufer, P. Romero and D.E. Speiser. Human
+
melanoma-specific CD8 T cells from metastases are capable of antigen-specific degranulation and cytolysis
directly ex vivo. OncoImmunology 2012. 1:467-530.
11.
Gupta B., E.M. Iancu, P.O. Gannon, S. Wieckowski, L. Baitsch, D.E. Speiser and N. Rufer. Simultaneous
co-expression of memory- and effector-related genes by individual human CD8 T cells depends on antigen
specificity and differentiation. Journal of Immunotherapy 2012. 35:488-501.
12.
Pasero C., D.E. Speiser, L. Derré and D. Olive. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Review Article. Current Opinion in Pharmacology 2012.
12:478-485.
13.
Goldinger, S.M., R. Dummer, P. Baumgaertner, D. Mihic, K. Schwarz, A. Hammann-Haenni, J. Willers, C.
Geldhof, J.O. Prior, T.M. Kuendig, O. Michielin, M.F. Bachmann and D.E. Speiser. Nano-particle vaccination
+
combined with TLR-7 and -9 ligands triggers memory and effector CD8 T cell responses in melanoma patients.
European Journal of Immunology 2012. 42:3049-3061.
Publications
-2-
Prof. Daniel Speiser
14.
Fuertes Marraco S.A., P. Baumgaertner, A. Legat, N. Rufer and D.E. Speiser. A stepwise protocol to coat
aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts. Journal of
Immunological Methods 2012. 385: 90-95.
15.
Kandalaft L.E., M. Kalos, C.J.M. Melief, D.E. Speiser and G. Goukos. Immune Signatures in the Tumor and
Beyond: Report of the Cancer Immunotherapy Consortium 2012 Scientific Colloquium. Immunotherapy 2012.
4:761-772.
16.
Hebeisen M., N. Rufer, S. Oberle, D.E. Speiser and D. Zehn. Signaling mechanisms that balance anti-viral,
auto-reactive, and anti-tumor potential of low-affinity T cells. Review Article. Journal of Clinical & Cellular
Immunology 2012. S12: 004.
www.omicsonline.org/ArchiveJCCI/SpecialissuesJCCI-S12.php
17.
Thibult M.L., J.P. Rivals, E. Mamessier, J. Gertner-Dardenne, S. Pastor, D.E. Speiser, L. Derré and D.
Olive. CpG-ODN induced sustained expression of BTLA mediating selective inhibition of human B cells. Journal of
Molecular Medicine 2013. 91:195-205.
18.
Corgnac S., L. Derré, R. Perret, L. Zhang, K. Stirnemann, M. Zauderer, D.E. Speiser, J.P. Mach, P.
Romero and A. Donda. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term
therapeutic responses. Cancer Immunology Immunotherapy 2013. 62:747-760.
19.
Gillessen S., U. Gnad-Vogt, E. Gallerani, J. Beck, C. Sessa, A. Omlin, M.R. Mattiacci, B. Liedert, D.
Kramer, J. Laurent, D.E. Speiser and R. Stupp. A phase I dose-escalation study of the immunocytokine EMD
521873 (Selectikine) in patients with advanced solid tumors. European Journal of Cancer 2013. 49:35-44.
20.
Bron L., C. Jandus, W. Seelentag, S. Andrejevic-Blant, D.E. Speiser, Ph. Monnier, P. Romero and J.P.
Rivals. Prognostic value of arginase-II expression and regulatory T cell infiltration in head and neck squamous cell
carcinoma. International Journal of Cancer 2013. 132:E85-93.
21.
Laurent J., C. Touvrey, S. Gillessen, C. Sessa, M. Vicari, S. Ongarello, B. Liedert, M. Joffraud, V.J.
Erpenbeck, F. Brichory, S. Quaratino, E. Gallerani, J. Beck, A. Omlin, R. Stupp, U. Gnad-Vogt and D.E. Speiser. T
cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.
Journal of Translational Medicine 2013. 11:5.
22.
Hebeisen M., L. Baitsch D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D.E. Speiser and N.
Rufer. Engineering of human CD8 T cells reveals TCR-affinity dependent functional inhibition via PD-1 and SHP-1.
Journal of Clinical Investigation 2013. 123:1044-1056.
23.
Speiser D.E. Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses.
Review Article. Cancer Discovery 2013. 3:379-381.
24.
Smulski CR, J. Beyrath, M. Decossas, N. Chekkat, P. Wolff, K. Gionnet, G. Guichard, D. Speiser, P.
Schneider and S. Fournel. Cysteine-rich domain one of CD40 mediates receptor self-assembly. Journal of
Biological Chemistry 2013. 288:10914-10922.
25.
Utzschneider D., A. Legat, S.A. Fuertes Marraco, L. Carrié, I. Luescher, D.E. Speiser and D. Zehn. T cells
maintain an exhausted phenotype following antigen withdrawal and re-expansion. Nature Immunology 2013.
14:603-610.
26.
Verdonck M., N. Wald, J. Janssis, P. Yan, C. Meyer, A. Legat, D.E. Speiser, C. Desmedt, D. Larsimont, C.
Sotiriou and E. Goormaghtigh. Breast cancer and melanoma cell line identification by FTIR imaging after formalinfixation and paraffin-embedding. Analyst 2013. 138:4083-4091.
27.
Hebeisen M., S. Oberle, D. Presotto, D.E. Speiser, D. Zehn and N. Rufer. Molecular insights for optimizing
T cell receptor specificity against cancer. Review Article. Frontiers in Immunology 2013. 4:154.
28.
Feldmeyer L., O. Gaide and D.E. Speiser. Clinical implications of CD8+ T cell infiltration in frequent and
rare cancers. Review Article. Journal of Investigative Dermatology 2013. 133:1929-1932.
29.
N. Rufer and D.E. Speiser. Molecular analysis of antigen specific CD8 T cells before and after
immunotherapy of melanoma patients. NCCR Molecular Oncology, Concluding Report 2013.
30.
Fagerberg Th., V. Zoete, S. Viatte, P. Baumgaertner, P.M. Alves, P. Romero, D.E. Speiser, J.C. Cerottini
and O. Michielin. Prediction of cross-recognition of peptide/HLA-A2 by Melan-A-specific CTLs using threedimensional quantitative structure-activity relationships. PLoS One 2013. 8(7), e65590.
Publications
-3-
Prof. Daniel Speiser
31.
Romano E., S. Pradervand, A. Paillusson, J. Weber, K. Harshman, K. Muehlethaler, D.E. Speiser, S.
V600E
Peters, D. Rimoldi and O. Michielin. Coexistence of divergent escape mechanisms in a patient with BRAF
mutated cutaneous melanoma treated with vemurafenib. Clinical Cancer Research 2013. 19:5749-5757.
32.
Robert-Tissot C., L.T. Nguyen, P. Ohashi and D.E. Speiser. Mobilizing and evaluating anti-cancer T cells:
pitfalls and solutions. Review Article. Expert Reviews of Vaccines 2013. 12: 1325-40.
33.
Iancu E.M., P.O. Gannon, J. Laurent, B. Gupta, P. Romero, E. Romano, D.E. Speiser and N. Rufer.
Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer
patients. PLoS One 2013. Oct 25;8(10):e78686.
34.
Legat A., D.E. Speiser*, H. Pircher, D. Zehn and S.A. Fuertes Marraco (*corresponding author). Inhibitory
receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T
cells. Frontiers in Immunology 2013. 4:455.
35.
Buchegger F., S.M. Larson, J.-P. Mach, Y. Chalandon, P.-Y. Dietrich, A. Cairoli, J.O. Prior, P. Romero and
D.E. Speiser. Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term
protective T cell immunity in follicular lymphoma patients. Review Article. Clinical and Developmental
Immunology 2013. 875343.
36.
Meyer C., L. Cagnon, C.M. Costa-Nunes, P. Baumgaertner, N. Montandon, L. Leyvraz, O. Michielin, E.
Romano and D.E. Speiser. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients
treated with Ipilimumab. Cancer Immunology Immunotherapy 2014. 63:247-257.
37.
Grusdat M., D.R. McIlwain, H.C. Xu, V.I. Pozdeev, J. Knievel, S.Q. Chrome, C. Robert-Tissot, R.J. Dress,
A.A. Pandyra, D.E. Speiser, E. Lang, S.K. Maney, A.R. Elford, S.R. Hamilton, S. Scheu, K. Pfeffer, J. Bode, H.-W.
Mittrücker, M. Lohoff, M. Huber, D. Häussinger, P.S. Ohashi, T.W. Mak, K.S. Lang and P.A. Lang. IRF4 and BATF
are critical for CD8+ T cell function following infection with LCMV. Cell Death and Differentiation 2014. 21: 10501060.
38.
Abate-Daga D., D.E. Speiser, N. Chinnasamy, Z. Zheng, H. Xu, S.A. Feldman, S.A. Rosenberg and R.A.
Morgan. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis
antigen SSX2 for adoptive immunotherapy of cancer. PLoS One 2014. Mar 28;9(3):e93321. doi:
10.1371/journal.pone.0093321.
39.
Romano E., O. Michielin, V. Voelter, J. Laurent, H. Bichat, A. Stravodimou, P. Romero, D.E. Speiser, F.
Triebel, S. Leyvraz and A. Harari. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients
receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. Journal of Translational Medicine
2014. 12:97.
40.
Mueller Ph., K. Martin, S. Theurich, J. Schreiner, S. Savic, G. Terszowski, D. Lardinois, V.A. HeinzelmannSchwarz, M. Schlaak, H.-M. Kvasnicka, G. Spagnoli, S. Dirnhofer, D.E. Speiser, M. von Bergwelt-Baildon and A.
Zippelius. Microtubule-depolymerizing agents used in antibody-drug-conjugates induce anti-tumor immunity by
stimulation of dendritic cells. Cancer Immunology Research 2014. 2:741-755.
41.
Romero P., D.E. Speiser, N. Rufer. Deciphering the unusual HLA-A2/Melan-A/MART-1 specific TCR
repertoire in humans. European Journal of Immunology 2014. 44:2567-2570.
42.
Kvistborg P., D. Philips, S. Kelderman, L. Hageman, Ch. Ottensmeier, M. Schoenmaekers-Welters, S. van
der Burg, E. Kapiteijn, O. Michielin, E. Romano, C. Linnemann, D.E. Speiser, Ch. Blank, J. Haanen and T.
Schumacher. Anti-CTLA4 therapy selectively induces novel melanoma-reactive CD8 T cell responses. Science
Translational Medicine 2014. Sep 17;6(254):254ra128.
43.
Speiser D.E., D.T. Utzschneider, S.G. Oberle, C. Münz, P. Romero and D. Zehn. T cell differentiation in
chronic infection and cancer – functional adaption or exhaustion? Review Article. Nature Reviews in Immunology
2014. 14:768-774.
44.
Romano E., M. Kusio-Kobialka, P.G. Foukas, H. Bichat, P. Baumgaertner, C. Meyer, P. Ballabeni, O.
Michielin, B. Weide, P. Romero and D.E. Speiser. FcgRIIIA (CD16)-expressing monocytes mediate the depletion of
tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients. Journal for Immunotherapy of
Cancer. 2014. 2(Suppl 3):O14.
45.
Bordry N., C. Costa-Nunes, L. Cagnon, P.O. Gannon, S. Abed Maillard, P. Baumgaertner, T. Murray, I.
Letovanec, R. Lazor, H. Bouchaab, N. Rufer, E. Romano, O. Michelin and D.E. Speiser. Pulmonary sarcoid-like
Publications
-4-
Prof. Daniel Speiser
granulomatosis after multiple vaccinations of a long–term surviving patient with metastatic melanoma. Cancer
Immunology Research 2014. 2:1148-1153.
46.
Flatz L. and D.E. Speiser. Immunologische Situation beim Melanom. Review Article. Review Onkologie
info@onkologie 2014. 4:5-7.
47.
Galluzzi, L., E. Vacchelli, J.-M. Bravo-San Pedro, A. Buqué, L. Senovilla, E.E. Baracco, N. Bloy, F.
Castoldi, J.-P. Abastado, P. Agostinis, R.N. Apte, F. Aranda, M. Ayyoub, P. Beckhove, J.-Y. Blay, L. Bracci, A.
Caignard, C. Castelli, F. Cavallo, E. Celis, V. Cerundolo, A. Clayton, M.P. Colombo, L. Coussens, M.V. Dhodapkar,
A.M. Eggermont, D.T. Fearon, W.H. Fridman, J. Fučíková, D.I. Gabrilovich, J. Galon, A. Garg, F. Ghiringhelli, G.
Giaccone, E. Gilboa, S. Gnjatic, A. Hoos, A. Hosmalin, D. Jäger, P. Kalinski, K. Kärre, O. Kepp, R. Kiessling, J.M.
Kirkwood, E. Klein, A. Knuth, C.E. Lewis, R. Liblau, M.T. Lotze, E. Lugli, J.-P. Mach, F. Mattei, D. Mavilio, I. Melero,
C.J. Melief, E.A. Mittendorf, L. Moretta, A. Odunsi, H. Okada, A.K. Palucka, M.E. Peter, K.J. Pienta, A. Porgador,
G.C. Prendergast, G.A. Rabinovich, N.P. Restifo, N. Rizvi, C. Sautes-Fridman, H. Schreiber, B. Seliger, H. Shiku,
B. Silva-Santos, M.J. Smyth, D.E. Speiser, R. Spisek, P.K. Srivastava, J.E. Talmadge, E. Tartour, S.H. van der
Burg, B.J. Van den Eynde, R. Vile, H. Wagner, J.S. Weber, T.L. Whiteside, J.D. Wolchok, L. Zitvogel, W. Zou and
G. Kroemer. Classification of current anticancer immunotherapies. Review Article. Oncotarget 2014. 5:1247212508.
48.
Speiser D.E. and L. Flatz. Cancer immunotherapy drives implementation science in oncology. Editorial /
Review Article. Human Vaccines & Immunotherapeutics 2014. 10:3107-3110.
49.
Wald N., A. Legat, C. Meyer, D.E. Speiser and E. Goormaghtigh. An infrared spectral signature of human
lymphocyte subpopulations from peripheral blood. Analyst 2015. 140:2257-2265.
50.
Fuertes Marraco S.A., C. Soneson, L. Cagnon, P.O. Gannon, S. Abed Maillard, N. Montandon, N. Rufer, S.
Waldvogel, M. Delorenzi and D.E. Speiser. Long-lasting memory CD8 T cells with highest “Naiveness” upon Yellow
Fever vaccination in humans. Science Translational Medicine 2015. 7, 282ra48.
51.
Hebeisen M., J. Schmidt, Ph. Guillaume, P. Baumgaertner, D.E. Speiser, I. Luescher and N. Rufer.
Identification of rare high avidity, tumor reactive CD8 T cells by monomeric TCR-ligand off-rates measurements on
living cells. Cancer Research 2015. 75:1983-1991.
52.
Romano E., M. Kusio-Kobialka, P.G. Foukas, P. Baumgaertner, C. Meyer, P. Ballabeni, O. Michielin, B.
Weide, P. Romero and D.E. Speiser. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo
by nonclassical monocytes in melanoma patients. Proc.Natl.Acad.Sci.U.S.A. 2015. 112:6140-6145.
53.
Gannon P.O., S. Wieckowski, P. Baumgaertner, M. Hebeisen, M. Allard, D.E. Speiser and N. Rufer.
Quantitative TCR:pMHC dissociation rate assessment by NTAmers reveals antimelanoma T cell repertoires
enriched for high functional competence. Journal of Immunology 2015. 195:356-366.
54.
Fuertes Marraco S.A., N.J. Neubert, G. Verdeil and D.E. Speiser. Inhibitory receptors beyond T cell
exhaustion. Review Article. Frontiers in Immunology 2015. 6: 310.
55.
Apetoh L., M.J. Smyth, C.G. Drake, J.-P. Abastado, R.N. Apte, M. Ayyoub, J.-Y. Blay, M. Bonneville, L.H.
Butterfield, A. Caignard, C. Castelli, F. Cavallo, E. Celis, L. Chen, M.P. Colombo, B. Comin-Anduix, G. Coukos,
M.V. Dhodapkar, G. Dranoff, I.H. Frazer, W.H. Fridman, D.I. Gabrilovich, E. Gilboa, S. Gnjatic, D. Jäger, P.
Kalinski, H.L. Kaufman, R. Kiessling, J. Kirkwood, A. Knuth, R. Liblau, M.T. Lotze, E. Lugli, F. Marincola, I. Melero,
C.J. Melief, T.R. Mempel, E.A. Mittendorf, K. Odun, W.W. Overwijk, A.K. Palucka, G. Parmiani, A. Ribas, P.
Romero, R.D. Schreiber, G. Schuler, P.K. Srivastava, E. Tartour, D. Valmori, S.H. van der Burg, P. van der
Bruggen, B.J. van den Eynde, E. Wang, W. Zou, T.L. Whiteside, D.E. Speiser, D.M. Pardoll, N.P. Restifo & A.C.
Anderson. Consensus nomenclature for CD8 T cell phenotypes in cancer. Review Article. OncoImmunology
2015. 4:4.
56.
Hurwitz A.A., S. Lee, S. Knox, H. Kohrt, G. Verdeil, E. Romano, K. Margolin, W. Urba and D.E. Speiser.
29th Annual Meeting of the Society of Immunotherapy of Cancer (SITC). Journal for Immunotherapy of Cancer
2015. 3:179.
57.
Chevalier M.F., S. Bobisse, C. Costa-Nunes, V. Cesson, P. Jichlinski, D.E. Speiser, A. Harari, G. Coukos,
P. Romero, D. Nardelli-Haefliger, C. Jandus and L. Derré. High-throughput monitoring of human T-cell responses
with large peptide pools. OncoImmunology 2015 May 27;4(10):e1029702
Publications
-5-
Prof. Daniel Speiser
58.
Giordano M., C. Henin, J. Maurizio, C. Imbratta, P. Bourdely, M. Buferne, L. Baitsch, L. Vanhille, M.H.
Sieweke, D.E. Speiser, N. Auphan-Anezin, A.-M. Schmitt-Verhulst and G. Verdeil. Molecular profiling of CD8 Tcells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO Journal 2015. 34:2042-2058.
59.
Fuertes Marraco S.A., C. Soneson, M. Delorenzi and D.E. Speiser. Genome-wide RNA profiling of longlasting stem-cell like memory CD8 T cells induced by Yellow Fever vaccination in humans. Genomics Data 2015.
5:297-301.
60.
Homicsko K., D.E. Speiser and O. Michielin. Avoiding Immune Destruction - Immunotherapy. Book Chapter
nd
in “ESMO Handbook of Translational Research”, 2 Edition 2015. G. Tortora, C. Sessa, A. Scarpa, S. Banerjee
(Eds). ESMO Press, Viganello-Lugano Switzerland. www.esmo.org
61.
Demaria O., A. De Gassart, S. Coso, N. Gestermann, J. Di Domizio, L. Flatz, O. Gaide, O. Michielin, P.
Hwu, T. Petrova, F. Martinon, D.E. Speiser and M. Gilliet. STING activation of tumor endothelial cells initiates
spontaneous and therapeutic antitumor immunity. Proc.Natl.Acad.Sci.U.S.A. 2015. 112:15408 -15413.
62.
Hebeisen M., M. Allard, P.O. Gannon, J. Schmidt, D.E. Speiser and N. Rufer. Identifying individual T cell
receptors of optimal avidity for tumor antigens. Review Article. Frontiers in Immunology 2015. 6:582.
63.
Verdeil G., S.A. Fuertes Marraco, T. Murray and D.E. Speiser. From T cell “exhaustion” to anti-cancer
immunity. Review Article. Biochim Biophys Acta (BBA) - Reviews on Cancer 2016. 1865:49-57.
64.
Legat A., H. Maby-El Hajjami, P. Baumgaertner, L. Cagnon, S. Abed Maillard, C. Geldhof, M. Iancu, L.
Lebon, Ph. Guillaume, D. Dojcinovic, O. Michielin, E. Romano, G. Berthod, D. Rimoldi, F. Triebel, I. Luescher, N.
Rufer and D.E. Speiser. Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T cell
responses in metastatic melanoma patients – report of a phase I/IIa clinical trial. Clinical Cancer Research 2016.
22:1330-40.
65.
Wald N., N. Bordry, P.G. Foukas, D.E. Speiser and E. Goormaghtigh. Identification of melanoma cells and
lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology. Biochim Biophys Acta
(BBA) - Molecular Basis of Disease 2016. 1862:202-212.
66.
Robert-Tissot C. and D.E. Speiser. Anti-cancer teamwork: Cross-presenting dendritic cells collaborate with
therapeutic monoclonal antibodies. Cancer Discovery 2016. 6:17-19.
67.
Neubert N.J., C. Soneson, D. Barras, P. Baumgaertner, D. Rimoldi, M. Delorenzi, S.A. Fuertes Marraco
and D.E. Speiser. A well-controlled experimental system to study CTL-melanoma cell interactions. Frontiers in
Immunology 2016. 7:326.
68.
Speiser D.E., P.-C. Ho and G. Verdeil. Regulatory circuits of T cell function in cancer. Review Article.
Nature Reviews in Immunology. 2016. 16: 599-611.
69.
Diem S., F. Keller, R. Rüesch, S. Abed Maillard, D.E. Speiser, R. Dummer, M. Siano, U. Urner-Bloch, S.M.
Goldinger and L. Flatz. Pembrolizumab - triggered uveitis - an additional surrogate marker for responders in
melanoma immunotherapy? Journal of Immunotherapy 2016. 39:379-382.
70.
Datta N.R., S. Krishnan, D.E. Speiser, E. Neufeld, N. Kuster, S. Bodis and H. Hofmann. Magnetic
nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich’s “magic (nano)bullet” for cancer
theranostics? Review Article. Cancer Treatment Reviews. 2016. 50: 217-217.
71.
Royer-Bertrand B., M. Torsello, D. Rimoldi, I. El Zaoui, K. Cisarova, R. Pescini-Gobert, F. Raynaud, L.
Zografos, A. Schalenbourg, D. Speiser, M. Nicolas, L. Vallat, R. Klein, S. Leyvraz, G. Ciriello, N. Riggi, A.P. Moulin
and C. Rivolta. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. The
American Journal of Human Genetics 2016. 99:1190-1198.
51
72.
Baumgaertner P., D.E. Speiser, N. Rufer and M. Hebeisen. Chromium-51 ( Cr) release assay to assess
human T cells for functional avidity and tumor cell recognition. Bio-Protocol 2016. Vol 6, Aug 20. www.bioprotocol.org/e1906
73.
Ascierto, P.A., M.L. Ascierto, S. Formenti, S. Gnjatic, H. Hammers, V. Hirsh, R. Kiessling, I. Melero, R.
Nanda, G. Pawelec, S. Pignata, P. Romero, D.E. Speiser, B.A. Fox and F. Marincola. Perspectives in
immunotherapy: Meeting report from the “Immunotherapy Bridge”. Napoli, December 5 th2015. Journal for
Immunotherapy of Cancer 2016. 4:62.
74.
Baumgaertner P., C. Costa Nunes, A. Cachot, H. Maby-El Hajjami, L. Cagnon, M. Braun, L. Derré, J.-P.
Rivals, D. Rimoldi, S. Gnjatic, S. Abed Maillard, P. Marcos Mondéjar, E. Romano, O. Michielin, P. Romero, C.
Publications
-6-
Prof. Daniel Speiser
Jandus* and D.E. Speiser* (*equal contributions). Vaccination of stage III/IV melanoma patients with long NY-ESO1 peptide and CpG-B elicits robust CD4+ and CD8+ T cell responses with multiple specificities including a novel
HLA-DR7 epitope. OncoImmunology 2016. 9;5(10):e1216290.
75.
Speiser D. Profitorientierte Wissenschaft is hinderlich. Leserbrief. Horizonte – Das Schweizer
Forschungsmagazin SNF 2016. 111:50.
76.
Jichlinski, P., L. Derre, D. Nardell-Haefliger, D. Speiser and P. Romero. Le traitement standard du cancer
de la vessie non musculo-invasif avec du BCG peut être associé à une vaccination anti-cancer pour augmenter la
réponse vaccinale cellulaire T locale. Progrès en Urologie 2016. 26:705.
77.
Chevalier, M., S. Trabanelli, D. Gharbi, V. Cesson, S. Domingos-Pereira, F. Dartiguenave, A. Fritschi, D.
Speiser, P. Romero, C. Jandus, D. Nardelli-Haefliger, L. Derre and P. Jichlinski. Analyse de l’infiltration immunitaire
au cours des instillations intravésicales de BCG: identification d’un profil immunosuppressif prédictif de la récidive
tumorale. Progrès en Urologie. 2016. 26:707.
78.
Hasan Ali, O., S. Diem, E. Markert, W. Jochum, K. Kerl, L. French, D.E. Speiser, M. Früh and L. Flatz.
Characterization of nivolumab associated skin reactions in patients with metastatic non-small cell lung cancer.
OncoImmunology 2016. 5(11): e1231292.
79.
Murray T., S.A. Fuertes Marraco, P. Baumgaertner, N. Bordry, L. Cagnon, A. Donda, P. Romero, G.
Verdeil and D.E. Speiser. Very Late Antigen-1 marks functional tumor-resident CD8 T cells and correlates with
survival of melanoma patients. Frontiers in Immunology 2016. 7:573.
80.
Gannon P.O., P. Baumgaertner, A. Huber, E.M. Iancu, L. Cagnon, S. Abed Maillard, H. Maby-El Hajjami,
N. Rufer* and D.E. Speiser* (*equal contributions). Rapid and continued T cell differentiation into long-term effector
and memory stem cells in vaccinated melanoma patients. Clinical Cancer Research 2016. Nov 21. doi:
10.1158/1078-0432.CCR-16-1708. Epub ahead of print.
81.
Derré L., V. Cesson, I. Lucca, Y. Cerantola, M. Valerio, U. Fritschi, Y. Vlamopoulos, R. Burruni, A.-S.
Legris, F. Dartiguenave, D. Gharbi, V. Martin, L. Vaucher, D.E. Speiser, P. Romero, P. Jichlinski and D. NardelliHaefliger. Intravesical Bacillus Calmette Guerin combined with a cancer vaccine increases local T-cell responses in
non-muscle-invasive bladder cancer patients. Clinical Cancer Research 2017. 23:717-725.
82.
Gattinoni L., D.E. Speiser, M. Lichterfeld and C. Bonini. T memory stem cells in health and disease: new
insights and therapeutic opportunities. Review Article. Nature Medicine 2017. 23:18-27.
83.
Chevalier M.F, P. Bohner, C. Pieraerts, B. Lhermitte, J. Gourmaud, A. Nobile, S. Rotman, V. Cesson, V.
Martin, A.-S. Legris, F. Dartiguenave, D. Gharbi, D.E. Speiser, L. De Leval, D. Nardelli-Haefliger, P. Jichlinski and
L. Derré. Immunoregulation of dendritic cells subsets by inhibitory receptors in urothelial cancer patients.
European Urology 2017. 71:854-857.
84.
Neubert N.J., L. Tille, D. Barras, C. Soneson, P. Baumgaertner, D. Rimoldi, D. Gfeller, M. Delorenzi, S.A.
Fuertes Marraco and D.E. Speiser. Broad and conserved immune regulation by genetically heterogeneous
melanoma cells. Cancer Research 2017. 77:1623-1636.
85.
Ioannidou K., P. Baumgaertner, P.O. Gannon, M.F. Speiser, M. Allard, M. Hebeisen, N. Rufer and D.E.
Speiser. Heterogeneity assessment of functional T cell avidity. Nature Scientific Reports 2017. Mar 13; 7:44320.
doi: 10.1038/srep44320.
86.
Spodzieja M., S. Lacha, J. Iwaszkiewicz, V. Cesson, K. Kalejta, D. Olive, O. Michielin, D.E. Speiser, V.
Zoete, L. Derré and S. Rodziewicz-Motowidło. Design of short peptides to block BTLA/HVEM interactions for
promoting anticancer T-cell responses. PLoS One 2017. Jun 8;12(6):e0179201.
87.
Murray T. and D.E. Speiser. Immune Cell Migration in Cancer and Immunotherapy. Book Chapter in
“Translational Cancer Research: Immunology to Immunotherapy”, Laurence Cooper and Elizabeth Mittendorf
(Eds), Wiley 2017. In press.
88.
Allard M., B. Couturaud, L. Carretero-Iglesia, M.N. Duong, J. Schmidt, G. Monnot, P. Romero, D.E.
Speiser, M. Hebeisen and N. Rufer. TCR-ligand dissociation rate is a robust and stable biomarker of CD8 T cell
potency. JCI Insight 2017. In press.
89.
Chevalier M.F, S. Trabanelli, J. Racle, V. Cesson, D. Gharbi, P. Bohner, S. Domingos-Pereira, F.
Dartiguenave, A.-S. Fritschi, D.E. Speiser, C.A. Rentsch, P. Romero, D. Gfeller, P. Jichlinski, D. Nardelli-Haefliger,
Publications
-7-
Prof. Daniel Speiser
C. Jandus and L. Derré. Local T-cell to MDSC balance is modulated by group-2 innate lymphoid cells and
predictive of bladder cancer recurrence. Journal of Clinical Investigation 2017. In press.